The Role of Cross-Sectional and Cohort Studies in Oncology

  • André Lopes Carvalho
  • Fabiana de Lima Vazquez
  • Cleyton Zanardo de Oliveira


Cross-sectional and cohort studies are important epidemiological study designs in oncology. In cross-sectional studies, information on exposure is collected at the same time as information on outcome. In oncology these studies are mainly performed to measure the prevalence of an outcome. There is no follow-up period for the study participants; thus we cannot establish the causality or association between exposure and the subsequent development of the disease under investigation, because we cannot determine what has occurred first (exposure-disease/cause-effect). These studies generate hypotheses for further investigation.

Cohort studies, on the other hand, are studies in which, from a potential baseline cause (exposure) one investigates its effect (outcome). Therefore, these studies represent a very good design for evaluating causality. They can be prospective or retrospective, and the study population is divided into subgroups according to exposure characteristics (exposed and not-exposed). The study then assesses outcome after a given period of time, allowing the measurement of association (relative risk) for the outcome to be observed in the exposed and the not-exposed individuals. In oncology, cohort studies are mostly used to study risk factors or prognostic factors.


Cross-sectional study Cohort study Exposure Outcome Risk factors Prognostic factors 


  1. 1.
    de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.CrossRefPubMedGoogle Scholar
  2. 2.
    Costa RFA, Longatto-Filho A, Pinheiro C, Zeferino LC, Fregnani JH. Historical analysis of the Brazilian cervical cancer screening program from 2006 to 2013: a time for reflection. PLoS One. 2015;10(9):e0138945.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013;105(14):1050–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Rogentine GN Jr, Yankee R, Gart J, Nam J, Trapani R. HL-A antigens and disease: acute lymphocytic leukemia. J Clin Investig. 1972;51(9):2420.CrossRefPubMedGoogle Scholar
  5. 5.
    Nalbandian A, Yan B, Pichugin A, Bronson R, Kramnik I. Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene. 2009;28(17):1928–38.CrossRefPubMedGoogle Scholar
  6. 6.
    Libshitz HI, Pannu HK, Elting LS, Cooksley CD. Tuberculosis in cancer patients: an update. J Thorac Imaging. 1997;12(1):41–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Lin W-W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5):1175–83.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Silva DR, Valentini DF Jr, Müller AM, de Almeida CP, Dalcin Pde T. Pulmonary tuberculosis and lung cancer: simultaneous and sequential occurrence. J Bras Pneumol. 2013;39(4):484–9.Google Scholar
  9. 9.
    Doll R, Peto R, Hall E, Wheatley K, Gray R. Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. BMJ. 1994;309(6959):911.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    López RVM, Levi JE, Eluf-Neto J, Koifman RJ, Koifman S, Curado MP, et al. Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection. Cancer Causes Control. 2014;25(4):461–71.CrossRefPubMedGoogle Scholar
  11. 11.
    Uzan VRM, van Helvoort Lengert A, Boldrini É, Penna V, Scapulatempo-Neto C, Scrideli CA, et al. High expression of HULC is associated with poor prognosis in osteosarcoma patients. PLoS One. 2016;11(6):e0156774.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Mork J, Lie AK, Glattre E, Clark S, Hallmans G, Jellum E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344(15):1125–31.CrossRefPubMedGoogle Scholar
  13. 13.
    Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK. AJCC cancer staging atlas: a companion to the seventh editions of the AJCC Cancer staging manual and handbook. New York, NY: Springer; 2012.CrossRefGoogle Scholar
  14. 14.
    Srivastava DK, Robison LL, Wu X, Rai SN. Design and analysis of cohort studies: issues and practices. Biom Biostat Int J. 2015;2(5):1–7.Google Scholar
  15. 15.
    Punt CJ, Buyse M, Köhne C-H, Hohenberger P, Labianca R, Schmoll HJ, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst. 2007;99(13):998–1003.CrossRefPubMedGoogle Scholar
  16. 16.
    Cornfield J. A method of estimating comparative rates from clinical data. Applications to cancer of the lung, breast, and cervix. J Natl Cancer Inst. 1951;11(6):1269–75.PubMedGoogle Scholar
  17. 17.
    Viera AJ. Odds ratios and risk ratios: what’s the difference and why does it matter? South Med J. 2008;101(7):730–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Little RJ, Rubin DB. Statistical analysis with missing data. Hoboken, NJ: John Wiley & Sons; 2014.Google Scholar
  19. 19.
    Kristman V, Manno M, Côté P. Loss to follow-up in cohort studies: how much is too much? Eur J Epidemiol. 2004;19(8):751–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Simon R, Wittes RE. Methodologic guidelines for reports of clinical trials. Cancer Treat Rep. 1985;69(1):1–3.PubMedGoogle Scholar
  21. 21.
    Priante AVM, Carvalho AL, Ribeiro KCB, Contesini H, Kowalski LP. The importance of long-term follow-up of head and neck cancer patients for reliable survival analysis. Otolaryngol Head Neck Surg. 2005;133(6):877–81.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • André Lopes Carvalho
    • 1
  • Fabiana de Lima Vazquez
    • 1
  • Cleyton Zanardo de Oliveira
    • 1
    • 2
  1. 1.Teaching and Research InstituteBarretos Cancer HospitalBarretosBrazil
  2. 2.Education and ResearchBP - A Beneficência Portuguesa de São PauloSão PauloBrazil

Personalised recommendations